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Background: Glioblastoma multiforme (GBM) is the most common primary brain tumour with 
dismal prognosis. GBMs are heterogenous tumours hence the name multiforme. The 
heterogeneity is reflected in histology, clinical presentation and genetic signature. The incidence 
of GBM is less than 10 to 100,000 but it accounts for 12-15% of all brain tumours. Exposure to 
ionizing radiation is the only known risk factor for developing glioma; there is no significant 
association reported with smoking, cellular phones, electromagnetic fields or diet. In GBM, the 
phosphoinositide 3-kinase/AKT (PI3K/AKT) pathway is dysregulated in about 89.6% of 
tumours and leads to increased activity in the protein kinase AKT. AKT promotes proliferation, 
cell survival and resistance to chemotherapy by regulation of various downstream effectors. 
Several AKT inhibitors are currently in clinical trials for different cancer types. However, the 
specific role of AKT inhibitors for GBM treatment is yet to be determined.  
In this study, allosteric and adenosine triphosphate (ATP) competitive kinase inhibitors of AKT 
were investigated in SKMG-3 (epidermal growth factor receptor (EGFR)-amplified; phosphatase 
and tensin homolog (PTEN)-null) and U-87 (EGFR-low, PTEN-null) GBM cell lines. It has been 
hypothesized that AKT inhibitors will induce cell death in GBM cell lines by blocking AKT 
activity. As such this project aims to investigate the effects of AKT inhibitors in vitro, determine 
the effects of AKT inhibitors on the clonogenic capacity and elucidate the cellular death 
mechanism induced by AKT inhibition. 
Methods: The cytotoxic effects of the drugs were determined by the cell viability assay based on 
cellular enzymatic activity. The antiproliferative effect of the AKT inhibitors was investigated by 
clonogenic assay. Western blot analysis was performed to evaluate the levels of apoptotic 
markers and phosphorylation status of downstream AKT substrates. Expression of phospho-AKT 
(Serine473) was visualized by immunofluorescence microscopy. 
Results: Among the inhibitors included in this study, MK-2206 and GSK-2141795 demonstrated 
superior therapeutic efficacy in both GBM cell lines. However, the EGFR amplified SKMG-3 
cell line was much more sensitive to AKT inhibitors compared to the U-87 cell line. The 
clonogenic potential of SKMG-3 cells was completely inhibited while some colonies of the U-87 
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cells survived in the given therapeutic regime. Cells treated with either compound showed 
decreased phosphorylation of the downstream substrate of AKT. This induced rapid apoptosis in 
SKMG-3 cells; however, apoptosis was not detectable upon AKT inhibition in U-87 cells. 
Conclusion and future perspectives: The results reported in this study indicate that AKT 
inhibitors should be further studied in vivo with a particular focus on the EGFR amplified 
subgroup. These AKT inhibitors can potentially be tested as a combinational therapy with EGFR 
inhibitors for achieving synergistic effects of the drugs and to overcome the drug resistance in 
EGFR amplified GBM. Moreover, targeting specific pathways may reduce adverse drug side 
effects. In future studies a panel of normal human astrocyte cell lines will be tested in vitro to 






1.1 Glioblastoma multiforme (GBM) 
GBM tumours are usually highly malignant, rapidly progressive astrocytoma with a median 
survival of 14-15 months (Stupp et al., 2005). The name GBM was first introduced by Mallory 
in 1914 due to the heterogenous nature of these tumours. As the incidence is fairly constant 
globally it is unlikely that environmental and geographical factors play a major role in the 
pathogenesis of GBM. Common clinical symptoms are dysphagia, seizures, headaches, cognitive 
changes, eye weakness and vomiting (Oberndorfer et al., 2008; Eefje et al., 2010). Progression 
of high intracranial pressure is one of the most dangerous features of GBM (Oberndorfer et al., 
2008; Pace et al., 2009). 
The incidence of GBM increases with age with a peak at 58 years. About 8.8% of children with 
central nervous system tumours have GBM (Dohrmann et al., 1976) and congenital cases are 
rare. Men are more prone to GBM slightly more than women, with a ratio of 3:2. The reason for 
this gender distribution is unknown (Iacob and Dinca, 2009). Gliomas usually appear 
sporadically but several genetic disorders are associated with increased incidence, including 
neurofibromatosis type-1 and type-2, Li–Fraumeni syndromes, von Hippel Lindau disease (Iacob 
and Dinca, 2009).  
The location of the tumour within the brain is variable (Holland, 2000). However, tumour cells 
are usually aggregated in the cerebral hemispheres with occasionally contralateral invasion and 
in association to the basal ganglia and lateral ventricles (Figure 1) (Lim et al., 2007). 
Depending on the cell of origin, gliomas can be divided into three subtypes: oligodendrogliomas, 
ependymomas and astrocytomas. Astrocytomas originate from astrocytes and invade through the 
normal brain tissue, which make it incurable by surgery. Around 35% of all brain tumours are 
astrocytomas which are histologically classified as low, intermediate or high grade. The highest 










Figure 1: Localization of GBM. Magnetic Resonance Image (MRI) showing a GBM as a 
contrast enhanced tumour in association with the lateral ventricle (Benedikte et al., 2010). 
The current standard care for GBM includes debulking surgery with focal fractionated 
radiotherapy with concomitant chemotherapy with Temozolomide. Aberration in oncogenic 
signaling pathways, diversity of mutated genes, tumour microenvironment and pathological 
angiogenesis are key prioritized areas in GBM. Several GBM candidate cancer genes (CAN-
genes) have been associated with GBM pathogenesis (Table 1). New targeted therapeutic 
approaches including inhibitors of growth factors and their receptors, intracellular signaling 
pathways and tumour angiogenesis are under investigation. For example, bevacizumab, an anti-
angiogenic agent has been shown a significant effect for treatment of recurrent GBM (Kreisl et 
al., 2009). However, the effect on overall survival did not reach statistical significance (Moller et 
al., 2012; Patel et al., 2012).  
1.2 Genetic aberrations in GBM 
Primary GBM: Primary GBMs arise as de novo that account for 95% of all GBM (Ohgaki and 
Kleihues, 2005). EGFR is frequently amplified in primary GBM (Kunihiko et al., 2008). In 
addition to EGFR over expression, PTEN mutations, cyclin-dependent kinase inhibitor-2A 
(CDKN2A) deletions and less frequently mouse double minute-2 homolog (MDM2) 






Table 1: Candidate cancer genes (CAN-genes) in GBM pathogenesis 
CAN-genes Proportion of 
alterations (%) 
References 
Catalytic subunit of phosphatidylinositol-3-kinase  
(PIK3CA) 
8 to 10 Mizoguchi et al., 2004; 
Parsons et al., 2008 
Cyclin-dependent kinase inhibitor-2A (CDKN2A) 50 Albert et al., 1987; 
Parsons et al., 2008 
Epidermal growth factor receptor (EGFR) 30 to 40 Albert et al., 1987; 
Parsons et al., 2008 
Phosphatase and tensin homolog (PTEN) 30 to 40 Li et al., 1997; Parsons et 
al., 2008 
Neurofibromatosis type-1 (NF1) 12 to 15 Mizoguchi et al., 2004; 
Parsons et al., 2008 
Retinoblastoma protein-1 (RB1) 12 to 15 Albert et al., 1987; 
Parsons et al., 2008 
Regulatory subunit of phosphatidylinositol-3-
kinase  (PIK3R1) 
8 to 10 Mizoguchi et al., 2004; 
Parsons et al., 2008 
Tumour  protein p53 (TP53) 30 to 40 Janice et al., 1989; 
Parsons et al., 2008 
Secondary GBM: Secondary GBMs arise from lower grade gliomas that constitute 5% of 
GBMs and mostly younger patients are affected (Ohgaki and Kleihues, 2005). Isocitrate 
dehydrogenase (IDH1) mutations are the earliest detectable precursor in low-grade diffuse 
astrocytomas and in oligodendrogliomas (Ohgaki and Kleihues, 2013). TP53 mutations occur 
with a high frequency in secondary GBM (Kunihiko et al., 2008). 
Common mutations: Loss of heterozygosity (LOH) mutation is the most common genetic 
alteration on the long arm of chromosome 10 and occurs in about 60 to 80% of both primary and 
secondary GBM (Ohgaki and Kleihues, 2007). 
1.3 Current histopathological classification 
Histopathological classification is based solely on morphology. Primary and secondary GBM 
show similar characteristics histologically but vary in their genetic and epigenetic profiles. 
Malignant diffuse gliomas include oligodendroglioma, astrocytoma and heterogeneous 
oligoastrocytic neoplasms (Louis et al., 2007). They are preferentially located in the frontal lobe 
and carry a significantly better prognosis and exert a lesser degree of necrosis (Ohgaki and 
Kleihues, 2013). Grade-I gliomas are characterized by low proliferative potential and are often 
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cured following surgical resection. Grade-II gliomas are generally infiltrative in nature and have 
a tendency to recur. Grade-III GBMs are characterized by nuclear atypia and mitotic activity. In 
most cases, patients of grade-III gliomas receive adjuvant radiation and/or chemotherapy. 
Pseudopalisading necrosis and/or microvascular proliferation is a characteristic for grade-IV 
astrocytoma (Miller and Perry, 2007). Grade-III and grade-IV tumours together comprise the 
clinical entity termed “malignant glioma” (Dunn et al., 2012). 
1.4 Tumour grades as prognostic factor 
Tumour grades I-IV are used to predict a response to therapy and outcome. Several parameters 
are considered to estimate the overall prognosis of each tumour entity such as the clinical 
findings (age of the patient, neurologic performance status and location of the tumour), 
radiological features (proliferation indices, extent of surgical resection) and genetic alterations. 
Patients with grade-II tumours typically survive more than 5 years but those with grade-III 
tumours survive 2–3 years (Louis et al., 2007). The overall survival is poor independent of 
treatment with grade-IV tumours (GBM).  
1.5 Regulation of AKT  
The PI3K/AKT signaling pathway is very crucial for maintaining many normal cellular 
functions. In GBM, the PI3K/AKT pathway is commonly deregulated. AKT is a master regulator 
in this pathway and belongs to the AGC protein kinase family. The term AGC kinase was 
proposed in 1995 to define the subgroup of Serine/Threonine protein kinases that are based on 
sequence homology of their catalytic kinase domain (Hanks and Hunter, 1995). The three 
isoforms of AKT are AKT1, AKT2, and AKT3. These multi-domain containing isoforms are 
highly homologous and contain an amino (N) terminal pleckstrin homology (PH) domain, inter 
domain linker, kinase domain and carboxy (C) terminal hydrophobic motif (HM) (Yang et al., 
2002; Kannan et al., 2007). These isoforms possess both common and distinct cellular functions. 
In normal cells, AKT regulates metabolism, growth, proliferation, differentiation and survival 
(Brazil et al., 2004; Carnero, 2010). Similar effects are identified for cancer cells where AKT in 
addition promotes resistance to cancer chemotherapy or radiotherapy (Winograd-Katz and 
Levitzki, 2006; Rao et al., 2012). 
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In this study, allosteric (MK-2206) and ATP competitive kinase inhibitors (GSK-2141795, 
GDC-0068, and GSK-690693) of AKT were investigated in two GBM cell lines, SKMG-3 and 
U-87. In the cell survival assay, MK-2206 and GSK-2141795 inhibitors demonstrated potent 
therapeutic efficacy in both cell lines. As such, these two inhibitors were used for the subsequent 
studies. 
PI3K/AKT pathway is regulated by a multistep process. The inactive form of AKT is termed the 
closed or ‘PH-in’ conformation (Wen et al., 2010) in which the PH domain interacts extensively 
with the kinase domain. Residues of the PH domain and ATP binding site are involved in inter 
domain interactions. AKT stays in a ‘PH-in’ conformation before being translocated and 
phosphorylated (Calleja et al., 2009). Upon receptor activation, adapter molecules such as the 
insulin receptor substrate (IRS) proteins bind to the receptor. This triggers activation of PI3K by 
interacting of its regulatory subunit with the bound adapter molecules. The catalytic domain of 
PI3K transforms phosphatidylinositol (3,4)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). AKT kinases are bound to PIP3 lipids through PH domain. This 
translocation allows phosphorylation at threonine 308 (Thr308) by phosphoinositide dependent 
protein kinase-1 (PDK1) that causes partial activation of AKT (Alessi et al., 1997). Full 
activation of AKT requires phosphorylation at Serine 473 (Ser473) in the carboxy-terminal 
hydrophobic motif, either by DNA-dependent protein kinase (DNAPK) (Feng et al., 2004) or 
mammalian target of rapamycin complex-2 (mTORC2) (Sarbassov et al., 2005) (Figure 2). To 
phosphorylate the downstream substrates of AKT, ATP must be localized in the ATP binding 
pocket of an activated AKT. Binding of ATP protects AKT from dephosphorylation until ATP is 
hydrolyzed into adenosine diphosphate (ADP), upon which a conformational change occurs that 
promotes the dephosphorylation and inactivation of AKT (Kui et al., 2012). Activation of AKT 
leads to phosphorylation of a variety of proteins, forkhead box O (FOXO), tuberous sclerosis 
proteins (TSC1/2), proline-rich AKT substrate of 40 kDa (PRAS40), glycogen synthase kinase 
(GSK3β) etc (Brendan and Lewis, 2007). Dephosphorylation of Thr308 by protein phosphatase 
2A (PP2A); Ser473 by PH-domain and leucine rich repeat protein phosphatase (PHLPP1/2) and 
the conversion of PIP3 to PIP2 by PTEN antagonize AKT signaling (Andjelkovic et al., 1996; 











Figure 2: Molecular mechanism of AKT activation. Interaction of a growth factor to the 
receptor allows binding of the adaptor molecules (IRS) to the receptor. This binding triggers 
PI3K activation that converts PIP2 to PIP3. AKT and PDK are bound to PIP3 by PH domain. 
Complete activation of AKT requires phosphorylation at Thr308 (T308) and Ser473 (S473) by 
PDK and mTORC2 respectively (Modified from Ronald et al., 2009). 
1.6 Mechanism of ATP competitive inhibitors 
Incubating cells with ATP competitive inhibitors of AKT induce hyperphosphorylation of 
Thr308 and Ser473 residues. These inhibitors mimic ATP and show higher binding affinity to 
the AKT binding site of an activated AKT (Wen et al., 2010). All AKT protein kinases have a 
similar protein fold that consists of two lobes: N-terminal lobe consists of mainly β-sheet 
structure and the C-terminal lobe consists of α-helices. This lobe structure creates an ATP-
binding cleft that constitutes the active site (Jeffrey and James, 2007). Activated AKT undergoes 
a substantial conformational change which renders phosphorylated sites inaccessible to 
phosphatases. Inhibitors bind to the ATP binding site of the AKT and appear to restrict intra and 
inter domain movement through their extensive contacts with residues in both lobes. In inhibited 
AKT, the phosphate group of Ser473 forms intra molecular interactions with Aspartic acid (Asp) 










































and Lysine (Lys297). These interactions are positioned close to the main surface of the kinase 
and do not protrude from the surface in an extended conformation, thus limiting the accessibility 
to phosphatases. In inactivated AKT, Tyrosine (Tyr229) is rotated into the ATP binding pocket, 
resisting binding of nucleotides or ATP competitive inhibitors. In addition, Phenylalanine 
(Phe293) exerts steric hindrance for inhibitor’s binding to the inactive, DFG (Asp-Phe-Gly)-out 
loop conformation (Kui et al., 2012). However, the PH domain cannot remain fully closed onto 
the kinase domain when ATP competitive inhibitors occupy the ATP binding site. Thus the 
phospholipid binding site of AKT becomes exposed which may increase the propensity of AKT 
to localize in the membrane (Wen et al., 2010). 
1.6.1 GSK-690693 
GSK-690693 (Figure 3) is an ATP competitive pan-AKT (Total AKT) kinase inhibitor. In vitro 
and in vivo studies of GSK-690693 in different cancer types have demonstrated that this 
compound inhibits AKT, and increases apoptosis (Deborah et al., 2010).  
 
Figure 3: Chemical structure of GSK-690693. The compound binds to the ATP binding pocket 
of AKT by making a key hydrogen bonding contact between N-5 of the oxadiazole moiety and 
the backbone NH of Alanine (Ala232) in the hinge-binding region. The hydrogen bonding 
network between the backbone NH of Phe294 and the side chain carboxylic acid of Glutamic 









GDC-0068 (Figure 4) is an orally bioavailable and potent pan-AKT inhibitor that can inhibit all 
three AKT isoforms. It demonstrates decreased viability of cancer cell lines and proficient 
antitumour response in xenograft models, resulting in the blockade of cell cycle progression 
(James et al., 2012; Lin et al., 2013). This compound is currently under evaluation in several 
clinical phase-I and II trials for the treatment of various human cancers including metastatic 
triple-negative breast cancer (Kim et al., 2015). 
 
Figure 4: Chemical structure of GDC-0068. The isopropylamine side chain interacts in the 
carbonyl rich region with the carboxylate side chains of Glu234 and Glu278. Pyrimidine ring of 
GDC-0068 interacts via a hydrogen bond to the amide NH of Ala230 in the hinge region of 
AKT. Target side chain of Ala230 in AKT creates a pocket that enables substitution of the GDC-
0068 core with various groups that afford a high degree of selectivity to AKT (James et al., 
2012). 
1.6.3 GSK-2141795 
GSK-2141795 (Figure 5) is orally bioavailable, and a potent ATP competitive inhibitor of all 
AKT isoforms. Preclinical studies had demonstrated that this compound inhibited proliferation of 
cancer cell lines. GSK-2141795 treatment decreases phosphorylation of downstream substrates 





with GSK-2141795 resulted in tumour growth inhibition and regression (Melissa et al., 2014). A 
phase-I study showed that this compound was well tolerated with reversible and predictable 
toxicities (Burris et al., 2011). 
 
Figure 5: Chemical structure of GSK-2141795. The compound binds to various residues of the 
ATP binding pocket of AKT (Dumble et al., 2014). 
1.7 Mechanism of allosteric inhibitors 
Generally, allosteric inhibitors bind to Tryptophan (Trp80) of the ‘PH-in’ conformation of AKT 
(Wen et al., 2010). These inhibitors inhibit both membrane association and activation of AKT 
(Barnett et al., 2005; Calleja et al., 2009). Mechanistically, they lock AKT into a closed 
conformation. In closed conformation, phospholipid binding site is blocked by the kinase 
domain. As a result, allosterically inhibited AKT remains cytosolic (Wen et al., 2010). As such, 
the loss of AKT conformational change upon inhibitor’s binding explains the loss of Thr308 
phosphorylation but is not a fully satisfactory explanation for the loss of Ser473 phosphorylation 
in the HM site. Loss of Ser473 phosphorylation may occur in two possible ways. First, binding 
of the inhibitors can lead to an incorrect positioning of the HM which may cause increased 
Ser473 dephosphorylation by phosphatases (Wen et al., 2010). Second, binding of inhibitors can 
create a steric hindrance that prevents the upstream kinase(s) from phosphorylating Ser473 
(Calleja et al., 2009). 
1.7.1 MK-2206 
MK-2206 (Figure 6) is an allosteric AKT inhibitor that is orally ingested. It inhibits all three 
forms of AKT but has a higher affinity for AKT1 by interaction with Trp80 of the pleckstrin-
homology domain (Mohd et al., 2014). This allosteric AKT inhibitor locks AKT in a closed 
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conformation with its phospholipid binding site blocked by the kinase domain thus inhibiting its 
subsequent activation (Wen et al., 2010; Liu et al., 2011; Knowles et al., 2011; Ma et al., 2013). 
MK-2206 has demonstrated preclinical efficacy in several cancer types (Meng et al., 2010; Hirai 
et al., 2010; Balasis et al., 2011) by inducing apoptosis (Cheng et al., 2012). MK-2206 at a dose 
of 135 mg/week is safe and well tolerated (Chien et al., 2016). 
 
 
Figure 6: Chemical structure of MK-2206. The two phenyl groups protruding from 
triazolonaphthyridin moiety bind with different residues especially with Trp80 within the 
allosteric site of AKT (Mohd et al., 2014). 
1.8 Cancer cell line as an in vitro model system to study cancer 
In vitro cancer models have offered great insights into cellular pathways and mechanisms 
involved in cancer cell biology (Gazdar et al., 2010). Cell lines usually provide the first proof-of-
principle for identifying new therapeutic targets. Since they harbor the essential cancer cell 
features such as an abnormal karyotype, uncontrolled proliferation, clonogenicity etc. The 
“Cancer Cell Line Encyclopedia” has compiled the molecular profiles of a large panel of human 
cancer cell lines (Barretina et al., 2012), and these profiles can be compared to a large panel of 
human tumours available in the “Cancer Genome Atlas Research Network” (Cancer Genome 
Atlas Research Network et al., 2013; Domcke et al., 2013). In this study, cancer cell lines were 
cultured in monolayer/2D layouts. However, there are some limitations of 2D in vitro assays 
since they may not accurately reflect the complex 3D tumour environment. Cell behaviour is 





highly dependent on interactions within a 3D environment. Indeed, 3D cultures offer more 
physiological conditions, similar to an in vivo situation, compared to monolayer cultures (Ravi et 
al., 2015). In our future studies, 3D culture conditions will be considered. 
1.9 In vitro cell viability assays  
Traditional methods such as counting viable cells based on trypan blue dye exclusion assay using 
a hemocytometer are simple but very time consuming and sometimes inaccurate (Kanemura et 
al., 2002). Now-a-days, a plethora of methods exist to assess the viability of in vitro cultured 
cells and cytotoxicity of compounds (Riss et al., 2013). Establishing a consistent and 
reproducible procedure is important. Depending on the methods of measurement these are often 
subdivided into four groups: clonogenic, radioactive, colorometric and fluorometric (Al-Nasiry 
et al., 2007; Vega-Avila and Pugsley, 2011). In this study, colorometric and clonogenic assays 
were performed.  
MTS (3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) - 2H-
tetrazolium) assay has been used since 1991 (Cory et al., 1991). It avoids the error prone 
solubilisation step which is required in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Dias et al., 1999). MTS assay is free from serious artifacts 
and uniquely precise (Goodwin et al., 1995). Viable cells reduce MTS into a soluble perceivable 
hue which is measured at 390 nm wavelength. Dead cells do not have this intrinsic ability to 
perform this activity, hence the colored product correlates with viable cells in culture (Cory et 
al., 1991; Riss et al., 2013). It is therefore possible to utilize this assay to predict cytotoxicity of 
any compound of interest. 
The clonogenic assay has been introduced for more than 50 years ago (Puck and Marcus, 1956). 
Clonogenic assay is the most widely used in vitro assay to determine the drug response to 
tumours that provides the medical oncologists with the necessary data to define beneficial drug 
regimens (Hoffman et al., 1991). At least in some cases clonogenic assay can partly replace 
animal studies for cancer drug evaluation (Hoffman et al., 1991). The survival of the 
proliferating cells is assessed by their ability to form colonies (Lu and Wong, 2005). The assay 
tests the ability of cells to undergo unlimited division. Cells are usually allowed to grow up to 1-
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3 weeks depending on their colony forming ability. After the incubation period, colonies are 
fixed and stained with glutaraldehyde and crystal violet respectively (Nicolaas et al., 2006). 
However, clonogenic assay has some limitations such as the ability to measure cell death at a 
low range of drugs, while clinical responses require a high dose range, clump artifacts, lack of 
cytotoxic end-points and loss of normal cell-cell interactions etc (Weisenthal et al., 1985; 
Hoffman et al., 1991). 
1.10 Target protein detection by Western blotting 
Western blotting has been in practice since 1979 (Towbin et al., 1979). It is one of the most 
important techniques used in cell and molecular biology to identify specific proteins from a 
complex mixture of proteins extracted from cells. Protein is separated by size, transferred to a 
solid support and visualized by using a proper primary and secondary antibody (Mahmood and 
Yang, 2012).  
One of the drawbacks of Western blotting is that the data produced are semi-quantitative. This is 
because, it provides a relative comparison of protein levels but not an absolute measure of 
quantity. The chemiluminescent signal generated during detection of proteins is not linear across 
the concentration range of samples (Mahmood and Yang, 2012). However, Western blot data are 
quantitatively interpreted in terms of fold changes in protein expression between samples (Sean 
et al., 2014). In this regard, appropriate selection of housekeeping proteins (HKPs) and total 
proteins are important for normalizing the data to assure that the reported fold changes of the 
target proteins are correct. 
1.11 In vitro cell based imaging by fluorescence microscopy 
Imaging is a valuable readouts of drug activity for in vitro cancer studies. Molecular imaging 
facilitates the assessment of the temporal and the spatial dissemination of biological processes in 
an intact living cell. With these approaches, more meaningful results can be achieved that are 
comparable with other in vitro methods (Weissleder, 2002). In imaging, tagged molecules can be 
viewed leading to insights on cell function, and the effectiveness of particular therapies (Cho et 
al., 2006; Sarker and Workman, 2007). However, a single technique alone is not sufficient to 
answer all the research quires. Therefore, techniques are chosen based on their feasibility. In our 
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study, fluorescence microscopy was used to visualize the expression of a fluorescently labeled 
phospho-AKT (Ser473) protein. 
Fluorescence microscopes were developed at the beginning of the 20th century (Köhler, 1905). 
Fluorescence microscopy is now being widely used in cell biological research to study fixed and 
living cells because of its versatility, specificity, and high sensitivity. Usually, mercury lamps are 
used as a light source for excitation of fluorochromes. Protein of interest can be marked with 
such fluorochromes via antibody staining which allows the assessment of the distribution of that 
single molecule species, its amount and localization inside a cell. A bandpass filter (excitation 
filter) is located between the light source and the specimen which efficiently restricts the range 
of excitation light. The excitation light excites the molecule to a higher level of vibrational 
energy, introducing an excited state. After the lifetime of the fluorescence agent, excited state 
returns to the ground state by releasing excess energy as a light photon (fluorescence emission). 
An emission filter (bandpass or longpass) is placed between the detector and the specimen that 
blocks the excitation light and allows only the emitted light to be transmitted (Figure 7). As the 
emitted light has a longer wavelength than the excited, hence the emitted light can pass through 
the emission filter that prevents the final image from distortions. The images are often detected 
by a charged couple device (CCD) or a photomultiplier tube (PMT) and displayed on a computer 
screen (Ishikawa-Ankerhold et al., 2012). Hoechst-33342 is often used in live cells (Purschke et 
al., 2010) and DAPI is often used in fixed cells to analyze DNA (Chazotte et al., 2011). A 
number of fluorochromes are available to mark the target proteins for example GFP (Benchaib et 
al., 1996). Photobleaching characteristic of the fluorochromes is a major problem associated with 
fluorescence microscopy. Reducing excitation light and exposure time can be beneficial to 












   
 
 
Figure 7: Principle of a fluorescence microscopy. Light of the desired excitation wavelength is 
focused on the specimen through the objective lens. The fluorescence emitted light is passed 
through the same objective to the detector (epifluorescence microscopy). A dichroic mirror 
allows the emitted light to pass through that prevents reflected excitation light entering the 
optics. Furthermore, emission filter is used to avoid the signal-to-noise ratio which only allows 
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Aims of the Study 
GBM poses a major medical challenge and the prognosis is dismal. De novo or acquired 
resistance to standard of care therapies is a major obstacle to effective treatment. As such, there 
is a need to develop new therapeutic agents. AKT is one of the key oncogenic kinases regulating 
gliomas. The main goal of the Master’s project was to investigate the AKT pathway using 
allosteric and ATP competitive inhibitors of AKT in GBM cell lines. In particular, the following 
objectives have been defined within the work: 
1. To investigate the therapeutic potential of AKT inhibitors in GBM cell lines with 
different genetic backgrounds 
2. To determine the antiproliferative effects of the AKT inhibitors in GBM 














Materials and Methods 
This study was conducted from 01 August 2015 to 01 April, 2016 at the Department of 
Biomedicine, University of Bergen, Norway to investigate the role of allosteric and ATP 
competitive kinase inhibitors of AKT in human GBM cell lines. 
3.1 Experimental cell lines 
 SKMG-3: PTEN-null , EGFR-amplified 
 U-87: PTEN-null , EGFR-low 
Cell lines were provided by the Department of Biomedicine, University of Bergen.  
3.2 Cell culture  
3.2.1 Equipments and reagents for cell culture 
 75 cm2 cell culture flasks (Thermo fisher scientific, USA) 
 DMEM medium (D5671, Sigma-Aldrich, UK) supplemented with necessary reagents 
 Trypsin EDTA (BE17-161E, Biowhittaker, Lonza, Belgium) 
 PBS (D1408, Sigma-Aldrich, USA) 
3.2.2 Reagents preparation for cell culture 
 1X PBS:  1X PBS was made by diluting 50 ml of 10X PBS in 450 ml Milli-Q water. 
3.2.3 Procedure of cell culture 
Cells were cultured in 75 cm
2 
culture flask, added with 20 ml of Dulbecco’s Modified Eagle’s 
Medium (DMEM). Media was supplemented with 50 ml of 11.11% fetal bovine serum (FBS), 10 
ml of 2.2% pen-strep, 10 ml of 2.2% L-glutamine, 16 ml of 3.5% non-essential amino acid 
(NEAA) and 100 µl of 0.02% plasmocin into 450 ml of DMEM. When cells reached 80% of 
confluency medium was removed from culture flask by aspiration and washed the monolayer 




 to remove all traces of serum. PBS solution was then 
removed by aspiration. 
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Sufficient volume of Trypsin/EDTA solution was dispensed into culture vessel to thoroughly 
cover the monolayer of cells and placed in 37°C incubator for around 3 minutes. Flasks were 
examined under an inverted microscope to check the detachment of cells from the surface. After 
trypsinization serum containing culture medium was added to the cell suspension to inhibit 
further trypsin activity which can damage cells. Trypsinization dissociated cells from each other 
and also from the surface of the culture flask. Cell suspension was gently pipetting up and down 
to break up the clumps. Passage number was demarcated on the flask after each passaging.  
3.3 Cell lines library construction  
3.3.1 Equipments for cell library construction 
 
 Cryovials (377224, Thermo fisher scientific, Denmark) 
 Centrifuge machine (5810R, Eppendorf, Germany) 
 -80 freezer/nitrogen tank 
 Disposable, sterile 50 ml falcon tubes 
 Isopropanol box 
 Automated Cell Counter (PHCC20060, Millipore, USA) 
 
3.3.2 Reagents for cell library construction 
 
 Freezing medium (8% DMSO, 20% fetus bovine serum, 72% DMEM medium) 
 
3.3.3 Procedure of cell library construction 
Library of cell lines was prepared considering the fact that these cells are valuable resources and 
their replacements are expensive and time consuming. Cells were frozen down and preserved for 
later use in case of any contamination or unwanted morphological changes of the running batch. 
Isopropanol box was kept at room temperature. Freezing medium was stored at -20°C freezer. 
Freezing medium was thawed before use. Adherent cells were gently detached from the culture 
flask and followed the procedure used during the subculture. Cells were resuspended in DMEM 
medium and the total number of cells was counted using an automated cell counter and desired 
volume of freezing medium was calculated (50,000 cells/ml). Cell suspension was centrifuged at 
600g for 5 minutes at 4°C. Supernatant was decanted inside the laminar air flow hood without 
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disturbing the cell pellet. Cell pellet was resuspended in cold freezing medium. Cell suspension 
was aliquoted into cryogenic storage vials and gently mixed the cells to maintain a homogeneous 
cell suspension. Cryovials containing the cells were kept in an isopropanol box and stored at -
80°C overnight. Frozen cells were then stored in the gas phase above the liquid nitrogen. 
3.4. Cell counting 
3.4.1 Equipments for cell counting 
 Automated cell counter with 60 µM sensors (PHCC20060, Millipore, USA) 
 Incubator 
3.4.2 Reagents for cell counting 
 Trypsin EDTA 
 DMEM medium supplemented with necessary reagents 
3.4.3 Procedure of cell counting 
Cells, about 80% of confluency were rinsed with 5 ml of 1X PBS and treated with 2 ml of 
trypsin EDTA. The flask was incubated for 3 minutes in the incubator (37°C and 5% CO2). 
Approximately, 10 ml of DMEM was added in the culture flask, pipetted up and down gently 
and the suspension was taken into a falcon tube. 100 µl cell suspension was taken into an 
eppendorf tube for cell counting by an automated cell counter.  
3.5 Cell viability assay 
3.5.1 Equipments for determining cell viability assay 
 96 well plates (167008, Thermo fisher scientific, Denmark) 
 Incubator (45762-2098, Forma scientific, USA) 





3.5.2 Reagents for determining cell viability assay 
 MTS (G3580, Promega, USA) 
 AKT inhibitors (GSK-2141795: A-1504, Active Biochem, USA; GDC-0068: A-1205, 
Active Biochem, USA; MK-2206: S1078, Selleckchem, Germany; GSK-690693: S113, 
Selleckchem, Germany) 
3.5.3 Principle of cell viability assay 
It is a colorimetric assay for assessing the cellular enzymatic activity. However, the exact 
mechanism of MTS reduction is not well understood but likely involves reaction with NADH or 
similar reducing molecules (O'Toole et al., 2003; Berridge et al., 2005). Tetrazolium reagent is 
used in combination with phenazine methyl sulfate (PMS), an intermediate electron acceptor. 
PMS which can enter into viable cells and transfer electrons from the cytoplasm or plasma 
membrane to enable the reduction of the tetrazolium into soluble formazan product. Formazan 
product that has an optimal absorbance at 390 nm.  
3.5.4 Procedure of cell viability assay 
5000 cells per 100 µl of medium were seeded in a 96 well plate and incubated overnight in an 
incubator. On the following day, cells were treated with increasing concentrations of drugs for 72 
hours. Allosteric and ATP competitive AKT inhibitors were used as the cell growth inhibitors. 
DMSO, resembling the highest concentration of the drugs was used as control. After 72 hours of 
drug treatment, 20 µl of MTS reagent was added to each well and incubated for 4 hours. 
Absorbance at 390 nm wavelength was measured by spectrophotometer. IC50 values were 
calculated using GraphPad Prism-6 software. IC50 value is the inhibitory concentration of a drug 
at which 50% inhibition of the cells attained in vitro. 
3.6 Clonogenic assay 
3.6.1 Equipments for clonogenic assay 





3.6.2 Reagents for clonogenic assay 
 Crystal violet dye 
 DMEM medium (10% FBS) 
 1X PBS 
 5% neutral buffered formaldehyde  
3.6.3 Procedure of clonogenic assay 
SKMG-3 and U-87 cells were seeded in 6 well plates (1,000 cells/well). After 24 hours, cells 
were treated with increasing concentrations of drugs and incubated for 11 days. Cells were 
grown in a humidified 5% CO2 environment at 37°C. In between the incubation period cells 
were replenished once with freshly prepared drugs. DMSO was used as a control.  
The procedures regarding on fixing and staining of colonies were performed in a fume hood. The 
media was gently removed from each of the wells by aspiration. Each well was washed with 1X 
PBS. Colonies were fixed with 5% neutral buffered formaldehyde solution for 15 minutes and 
stained with 0.01% (w/v) crystal violet in dH2O for 30 minutes. Excess crystal violet dye was 
washed with dH2O. 
3.6.4 Quantification of colonies 
3.6.4.1 Equipments for colony quantification 
 Spectrophotometer 
 
3.6.4.2 Reagents for colony quantification 
 10% acetic acid 
 
3.6.4.3 Procedure of colony quantification 
 
The crystal violet staining of cells was solubilized in 10% acetic acid. The absorbance of the 




3.7 Quantification of total protein concentration  
3.7.1 Equipments for quantification of total protein concentration 
 96 well plates 
 Incubator  
 Spectrophotometer  
3.7.2 Reagents for quantification of total protein concentration 
 Bicinchoninic acid (BCA) Reagent A (QD215382, Thermo fisher scientific, USA). BCA 
Reagent A contains sodium carbonate, sodium bicarbonate, pierce BCA detection 
reagent, and sodium tartrate in 0.1 N sodium hydroxide. 
 BCA Reagent B (1859078, Thermo fisher scientific, USA). BCA Reagent B contains 
cupric (II) sulfate 
 RIPA buffer (89900, Thermo fisher scientific, USA) 
3.7.3 Reagents preparation for quantification of total protein concentration 
 Mixed BCA reagent: 9.8 ml BCA reagent A was mixed with 200 µl BCA reagent B to 
make 10 ml of mixer solution. 
 RIPA buffer solution: The solution contains 5 mM Tris HCl (pH 7.6), 150 mM NaCl, 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS. In addition, 1 tablet of protease 
inhibitor (S8820, SigmaFast™, USA) and 1 tablet of phosphatase inhibitor 
(04906837001, Roche, Germany) were dissolved in 10 ml of RIPA buffer. 
3.7.4 Principle of BCA assay 




to cuprous ions 
(Cu
+
) by the proteins in an alkaline condition (the biuret reaction) which are then chelated by 
BCA. Each Cu
+
 cation is chelated by two molecules of BCA that produces a water soluble purple 
colored reaction product which is measured at 562 nm. The absorbance has a linear correlation 
with increasing protein concentrations over a broad range of 20 to 2000 µg/ml.  
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3.7.5 Procedure of quantification of total protein concentration 
The cultured cells were harvested by the scraper and taken into the eppendorf tubes and 
immediately lysed by the lysis buffer. The lysed cells were sonicated (60 seconds) for disrupting 
the cell membrane. In a 96 well plate, 200 μl of BCA mixture solution was added in each well. 
Standards and samples were loaded as triplicates, 2 μl each. The plate was then incubated at 
37°C for 45 minutes with gentle shaking. The absorbance was taken at 562 nm by 
spectrophotometer. Bovine serum albumin was used as a protein standard that was serially 
diluted with the blocking buffer at a 1:1 ratio (Figure 8). The standard curve analysis (Y=a+bx, 
Y=known absorbance, a=slope, b=y intercept and x=unknown concentration) was used to 
measure the total protein concentration.  
3.8 Western blotting 
Western blotting was performed to identify the target proteins from a complex mixture of 
proteins extracted from cells treated with control (DMSO), AKT inhibitors, Staurosporine (S-
4400, Sigma-Aldrich, USA). The technique follows three steps: (1) gel electrophoresis to 
separate proteins by size (2) electrotransfer to a solid support and (3) tagging target protein with 
a proper primary and secondary antibody to visualize (Mahmood and Yang, 2012). 
3.8.1 Gel electrophoresis 
3.8.1.1 Equipments for gel electrophoresis 
 Nupage™ Precast Gel (4-12%) (NP0321BOX, Thermo fisher scientific, USA) 
 Gel electrophoresis cassette 
 Power supply system (164-5050, PowerPac™, Bio-Red, USA) 
 
3.8.1.2 Reagents for gel electrophoresis  
 2X Laemmli sample buffer (161-0737, Bio-Rad, USA) 





















Figure 8: BSA stock solution preparation (125-2000 µg/ml). The standard, bovine serum 
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3.8.1.3 Reagents preparation for gel electrophoresis 
 Laemmli sample buffer: 2X Laemmli sample buffer contains a mixture of 65.8 mM 
Tris-HCl (pH 6.8), 26.3% (w/v) glycerol, 2.1% SDS and 0.01% bromophenol blue. The 
pH of the solution is 6.8. Reducing agent, β-mercaptoethanol (10%) was added to the 
buffer prior to mixing with the sample. The β-mercaptoethanol facilitates proper 
separation of the proteins based on their size by reducing inter and intra molecular 
disulfide bonds of the proteins. The SDS detergent does not only denature the proteins 
but also binds to the positive charges of a protein. Thus giving each protein the same 
overall negative charge for which proteins are separated based on their size. 
Bromophenol blue is used as an indicator dye. Glycerol increases the density of the 
sample so that sample does not come out from the well.  
 
 MOPS running buffer (1X): Milli-Q water, 950 ml was added into 50 ml of 20X stock 
solution to make 1L of 1X Running buffer. The composition of 20X MOPS stock 
solution is 50 mM MOPS (3-(N-morpholino) propane sulfonic acid), 50 mM Tris Base, 
0.1% SDS, 1 mM EDTA. The solution has a pH of 7.7.  
3.8.1.4 Sample preparation for gel electrophoresis 
Sample volume that contains 20 µg of protein was taken (calculated from the standard curve 
analysis) in an eppendorf tube. 2X laemmli sample buffer was added as the half volume of the 
sample to maintain its concentration of 1X. The sample mixture was then heated at 70° for 10 
minutes. 
3.8.1.5 Procedure of gel electrophoresis 
Precast Gel (4-12%) was used to separate the polypeptides by size. The white tape at the bottom 
of the gel cassette was removed and then placed in the slot of the Criterion™ tank. The chamber 
of the tank was blocked by a barrage and locked. The chamber was filled by around 50 ml of 
fresh 1X running buffer and the rest of the tank was filled by previously used running buffer 
(approximately 400 ml). The comb of the wells was removed carefully by pulling upward. The 
protein standard ladder and prepared samples were loaded in the wells of the gel using a 
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micropipette with gel loading tips. The lid was fit onto the tank and plugged into the power 
source. The electrophoresis was run for about one and half hour (150V). Electrophoresed gel was 
drawn from the gel cassette and the tank was rinsed with UF (Ultrafiltration) water. 
3.8.2 Electrotransfer of proteins 
3.8.2.1 Equipments for electrotransfer of proteins 
 Plastic cassette 
 Paper pad 
 Gel  
 Nitrocellulose membrane (G9890277, GE healthcare life sciences, Germany) 
 Roller 
3.8.2.2 Reagents for electrotransfer of proteins  
 Transfer buffer (1676236, Novex, Life technologies, USA) 
3.8.2.3 Reagents preparation for electrotransfer of proteins  
 Transfer buffer (1X): 850 ml of Milli-Q water and 100 ml of methanol were added into 
50 ml of 20X stock solution to make 1L of 1X Transfer buffer. The composition of 20X 
stock solution is 25 mM Bicine, 25 mM Bis-Tris (free base), 1 mM EDTA. The pH of the 
stock solution is 7.2.  
3.8.2.4 Procedure of electrotransfer of proteins 
In electrophoretic transfer, an electric field was employed to elute the proteins from 
electrophoresed gel and transfer them to the nitrocellulose membrane. A nitrocellulose 
membrane and the gel were placed together, with one filter paper and four fiber pads on top and 
bottom of the gel (Figure 9). Air bubbles formed between the gel and the nitrocellulose 
membrane were removed by gentle rolling using the roller tool. The sandwich was then placed in 
the blotting tank. Fresh transfer buffer was poured over the sandwich and the rest of the tank was 
filled with previously used transfer buffer. The lid was fit onto the tank and plugged into the 







   
 
 
Figure 9: The orientation of a gel sandwich. Nitrocellulose membrane and gel are placed 
between buffer soaked filter papers. Fiber pads are placed at each end of the sandwich. 
3.8.3 Blocking, antibody incubation and detection 
3.8.3.1 Reagents for blocking, antibody incubation, and detection 
 Phosphate buffer saline Tween (1X PBST) 
 Blocking solution 
 Primary antibody  
 Secondary antibody (PH18900721, Thermo fisher scientific, USA) 
 Enhanced chemiluminescent substrate (34095, Thermo fisher scientific, USA) 
 Image Reader LAS-3000 (4622724, Fujifilm, Japan) 
3.8.3.2 Reagents preparation for blocking, antibody incubation and detection 
 Phosphate buffer saline Tween (PBST): 0.1% Tween-20 was mixed into 1X PBS. 
 Blocking solution: 5% skim milk powder was mixed in 1X PBST. Hence 25 gm milk 
powder was mixed in 1X PBST. 
 Primary antibody: Primary antibodies (Table 2) were diluted in blocking solution as 
1:5000.  











 Enhanced chemiluminescent substrate: Super Signal West Femto Maximum Sensitivity 
Substrate A (1 ml) was mixed with B (1 ml). Super Signal West Femto Maximum 
Sensitivity Substrate is very sensitive that can detect low femtogram amounts of protein in 
bands on nitrocellulose membranes. 
 
Table 2: Primary antibodies for Western blotting 
Primary antibody Catalogue number Supplier 
Phospho-AKT (Ser473) 4058 Cell signaling technology, USA 
pan AKT 4685 Cell signaling technology, USA 
Phospho-PRAS40 2997 Cell signaling technology, USA 
PRAS40 2691 Cell signaling technology, USA 
PARP 9542 Cell signaling technology, USA 
Cleaved caspase 3 (Asp175) 9661 Cell signaling technology, USA 
GAPDH ab9485 Abcam, UK 
 
3.8.3.3 Procedure of blocking, antibody incubation and detection 
The blots were incubated with specific primary and secondary antibodies respectively to 
visualize the desired proteins. Nitrocellulose membrane was incubated with blocking solution for 
an hour on a shaker to block the protein free spaces on the membrane (5% skim milk in 1X 
PBST). The membrane was rinsed three times in 1X PBST, 10 minutes each. The primary 
antibodies were diluted as 1:5000 in the blocking solution. The blots were incubated with 
specific primary antibodies overnight at 4°C on a shaker. On the following day, blots were rinsed 
three times in 1X PBST, 10 minutes each. The secondary antibody (anti rabbit) was diluted in 
PBST at 1:10,000 ratio. The blots were then incubated with the diluted secondary antibody for 1 
hour at room temperature on an electric shaker. After that, blots were rinsed three times in PBST, 
10 minutes each. Chemiluminescence detection technique, subjected to secondary antibody 
conjugated HRP enzyme and ECL substrate reaction, was used to detect the blotted proteins. A 
chemiluminescence product was formed upon addition of ECL substrate that was visualized in a 
digital imaging system (Image Reader LAS-3000).   
3.8.4 Protein standard 
The SeeBlue Plus2 Pre-Stained Standard (LC5925, Invitrogen, USA) contains a total of ten 
proteins. The protein mixture allows approximate calibrations of proteins in a mass range 
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between ~14 and 191 kDa. The standard allows quick visual assessment during electrophoresis 
and transfer. 
3.9 Immunocytochemistry 
3.9.1 Equipments for immunocytochemistry 
 Fluorescence microscope (3512000236, Zeiss AXIOZ1, Germany) 
 Glass cover slips (J1800AMNZ, Thermo fisher scientific, Germany) 
 24 well plates 
 
3.9.2 Reagents for immunocytochemistry 
 4% formaldehyde 
 1X PBS 
 0.5% Triton X-100 
 Primary antibody, phospho-AKT (Ser473)  
 FITC conjugated anti rabbit secondary antibody (4010-02, SouthernBiotech, USA) 
 Prolong Gold antifade reagent with DAPI (P36935, Molecular probes, USA) 
3.9.3 Procedure of immunocytochemistry 
Cells were seeded onto glass cover slips at 1000 cells/ml in 24 well plates. On the following day, 
cells were treated with drugs for 24 hours. Cells were then fixed with 4% formaldehyde in 
1XPBS for 30 minutes at room temperature (RT). Fixed cells were washed with 1X PBS and 
permeabilized with 0.5% Triton X-100 in PBS for 4 minutes. After washing three times with 
PBS, the cover slips were incubated in blocking buffer (0.5% BSA in PBS, sterile filtered) for 15 
minutes at room temperature. Cover slips were then incubated with phospho-AKT (Ser473) 
antibody (diluted 1:100 in blocking buffer) for 24 hours at 4°C. Wet paper towel was kept in the 
box to prevent the slides from drying. They were then washed twice with PBS, followed by 
incubation with FITC conjugated anti rabbit for 30 minutes at RT. After washing three times 
with PBS, the cover slips were mounted with 5 μM of Prolong Gold antifade reagent containing 
DAPI. Cells were examined under a Ziess fluorescence microscope with a 63X oil objective with 
29 
 
DAPI and FITC filter for visualizing nuclear staining and target protein coupled with FITC 
respectively (Figure 10). Axiovision Rel 4.8 software was used to capture the images. Two 
pictures of one cell (one was with DAPI and another with FITC filter) were overlaid in ImageJ 
software. 
3.10 Statistical analysis 
In this study, all the statistical analyses were performed by GraphPad Prism-6 software. The IC50 
values of the cell viability experiment were analyzed by two tailed t-test. In clonogenic 







Figure 10: Immunofluorescent labeling of the target protein. Cells are fixed on the glass 
cover slide and then permeabilized. The epitopes of the target protein are bound with the specific 
primary antibody. The attached antibody is then bound with fluorescent labeled secondary 




















4.1 AKT inhibitors impair viability in human GBM cells 
GBM cells were cultured in DMEM medium supplemented with 10% fetal bovine serum. Cells 
were treated with a series of concentrations of AKT inhibitors (MK-2206, GSK-2141795, GDC-
0068, and GSK-690693) for 72 hours. Cell viability was measured by MTS assay. IC50 values 
were assessed using GraphPad Prism-6 software (Figure 11: A; Figure 12: A; Figure 13: A; 
Figure 14: A). IC50 value is the inhibitory concentration of a drug that determines the 50% 







Figure 11: Effects of GSK-690693 on viability in U-87 and SKMG-3 GBM cells. (A) 
Viability was determined after increasing concentrations of GSK-690693. Each value (mean ± 
standard deviation, n= 3) of the survival rate is the percentage for the cells exposed to the drug. 
IC50 values of GSK-690693 in U-87 and SKMG-3 cells were 34.8 and 8.2 μM respectively. (B) 
IC50 values were used to test the significance of the drug response between the two cell lines. P 
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Figure 12: Effects of GDC-0068 on viability in U-87 and SKMG-3 GBM cells. (A) Viability 
was determined after increasing concentrations of GDC-0068. Each value (mean ± standard 
deviation, n= 3) of the survival rate is the percentage for the cells exposed to the drug. IC50 
values of GDC-0068 in U-87 and SKMG-3 cells were 88.5 and 1.7 μM respectively. (B) IC50 
values were used to test the significance of the drug response between the two cell lines. P value 







Figure 13: Effects of MK-2206 on viability in U-87 and SKMG-3 GBM cells. (A) Viability 
was determined after increasing concentrations of MK-2206. Each value (mean ± standard 
deviation, n= 3) of the survival rate is the percentage for the cells exposed to drug. IC50 values of 
MK-2206 in U-87 and SKMG-3 cells were 9.3 and 6.1 μM respectively. (B) IC50 values were 
used to test the significance of the drug response between the two cell lines. P value (= 0.0006), 
determined from the two tailed t-test was found significant. 
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Figure 14: Effects of GSK-2141795 on viability in U-87 and SKMG-3 GBM cells. (A) 
Viability was determined after increasing concentrations of GSK-2141795. Each value (mean ± 
standard deviation, n= 3) of the survival rate is the percentage for the cells exposed to the drug. 
IC50 values of GSK-2141795 in U-87 and SKMG-3 cells were 9.7 and 4.4 μM respectively. (B) 
IC50 values were used to test the significance of the drug response between these two cell lines. P 
value (<0.0001), determined from the two tailed t-test was found significant. 
4.2 AKT inhibitors reduce clonogenicity in GBM cells 
The antiproliferative effect of the AKT inhibitors was investigated by clonogenic assay. In each 
well of a 6 well plate, 1000 cells were seeded. Cells were plated as triplicates. On the following 
day, cells were treated with MK-2206 and GSK-2141795 at concentrations of 2, 5, and 7 μM as 
monotherapy and DMSO as control (Figure 15: A; Figure 16: A). Cells were incubated for 11 
days until colonies were clearly seen. Colonies were stained by 0.01% crystal violet dye 
(Franken et al., 2006) that primarily binds to DNA in the nucleus of mammalian cells (Gillies et 
al., 1986). Colonies were quantified by dissolving the crystal violet staining of the cells in 10% 
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Figure 15:  Effects of AKT inhibition on clonogenicity in SKMG-3 cells. (A) Representative 
images of the clonogenic assay of SKMG-3 cells treated with increasing concentrations of AKT 
inhibitors and DMSO. (B, C) Colonies were quantified by dissolving the crystal violet staining of 
the cells in 10% acetic acid. The absorbance of the solution was measured at a wavelength of 590 
nm. The data in the graphs were presented as mean ± SD (n= 3). These are the representative 
results of two independent experiments.   
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Figure 16: Effects of AKT inhibition on clonogenicity in U-87 cells. (A) Representative 
images of the clonogenic assay of U-87 cells treated with increasing concentrations of AKT 
inhibitors and DMSO. (B, C) Crystal violet staining of cells from each well was dissolved in 
10% acetic acid for colony quantification. The absorbance of the solution was measured at a 
wavelength of 590 nm. The data in the graphs were presented as mean ± SD (n= 3). These are 
the representative results of two independent experiments. 
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4.3 AKT inhibitors affect phosphorylation of AKT and its downstream substrates  
The two AKT inhibitors affected AKT-phosphorylation differently. MK-2206 decreased while 
GSK-2141795 increased phosphorylation of AKT (Figure 17: A; Figure 18: A). Decreased 
phosphorylation of PRAS40, a downstream substrate of AKT was determined (Figure 17: A, B; 
Figure 18: A, B). Drugs increased the levels of cleaved caspase 3, an apoptotic maker, in SKMG-
3 cells (Figure 17: A) while no induction of cleaved caspase 3 was determined in U-87 cells 
(Figure 18: A). However, apoptosis inducing chemotherapeutic, Staurosporine showed that 
apoptosis pathway was prevailed in U-87 cells as determined by the increased levels of caspase 3 








Figure 17: Assessing the effects of AKT inhibitors on downstream substrates of AKT and 
apoptotic markers in SKMG-3 cells. (A) Western blotting of phospho-AKT (Ser473), pan-
AKT, cleaved caspase 3, phospho-PRAS40, PRAS40, PARP, and cleaved PARP was performed 
in protein extracts of SKMG-3 cells treated with drug control and AKT inhibitors for 24 hours at 
9 μM. The blots are representative of two independent experiments. (B) Phospho-PRAS40 was 

























































Figure 18: Assessment the effects of AKT inhibitors on downstream substrates of AKT and 
apoptotic markers in U-87 cells. (A) Western blotting of phospho-AKT (Ser473), pan-AKT, 
cleaved caspase 3, phospho-PRAS40, PRAS40, PARP, and cleaved PARP was performed in 
protein extracts of U-87 cells treated with drug control and AKT inhibitors for 24 hours at 9 μM. 
The blots are representative of two independent experiments. (B) Phospho-PRAS40 was 
normalized to its respective total protein and presented as relative fold change.  
 
 
Figure 19: Staurosporine induces apoptosis in U-87 cells. Cells were incubated with 5 μM of 
Staurosporine and DMSO as control for 24 hours. Staurosporine increased the levels of cleaved 

























































4.4 Determining the expression of phospho-AKT by immunofluorescence 
To further substantiate the Western blot data the levels of expression of phospho-AKT (Ser473) 
were assessed by immunofluorescence staining. It has been demonstrated that the levels of 
phosphorylation of AKT at 473 was reduced significantly by MK-2206 (Figure 20: B; Figure 21: 
B) compared to the control group (Figure 20: A; Figure 21: A). While GSK-2141795 
hyperphosphorylated AKT at 473 (Figure 20: C; Figure 21: C). The levels of pan-AKT (Total 









Figure 20: Immunofluorescence staining of phospho-AKT (Ser473) in SKMG-3 cells. 
Expression of phospho-AKT (Ser473) in SKMG-3 cells treated with (A) DMSO, (B) MK-2206 
at 6 μM, (C) GSK-2141795 at 6 μM. All the representative images were acquired after 24 hours 
of incubation of the cells with drugs and control. Host cell DNA was visualized with DAPI. 
Phospho-AKT (Ser473) was visualized with FITC fluorophore. Green and blue channels were 




















Figure 21: Immunofluorescence staining of phospho-AKT (Ser473) in U-87 cells. Expression 
of phospho-AKT (Ser473) in U-87 cells treated with (A) DMSO, (B) MK-2206 at 7 μM, (C) 
GSK-2141795 at 7 μM. All the representative images were acquired after 24 hours of incubation 
of the cells with drugs and control. Host cell DNA was visualized with DAPI. Phospho-AKT 
(Ser473) was visualized with FITC fluorophore. Green and blue channels were superimposed on 




















Glioblastoma is the most common primary brain tumour with a median survival of 14-15 months 
(Stupp et al., 2005). Various therapeutic approaches targeting the key molecular pathways are 
being studied in preclinical and clinical trials (Vacchelli et al., 2014). Individualized cancer 
therapy is no more a myth and allows for deciphering accurate individualized predictions of the 
likelihood of developing a disease, prognosis of the disease, and the disease susceptibility to the 
therapeutic agents. Each patient's genetic and clinical information are considered during this 
process (Van et al., 2010). Thus, individualized medicine helps to choose better targeted 
therapies and reduce healthcare costs. Although these approaches are promising, there are 
potential caveats to these strategies, including serious or unexpected toxic effects or the 
emergence of drug resistance (Shah et al., 2012; Lu-Emerson et al., 2015). Strategies involving 
dose escalation or combinations with other agents can be undertaken to overcome such problems. 
However, data are limited in support of such an approach for GBM, and personalized medicines 
are not yet available in contemporary clinical neuro-oncology practice. Novel therapies targeting 
specific molecular pathways may offer superior efficacy and less toxicity than conventional 
therapies but initial clinical trials of molecularly targeted agents in brain cancer therapy are 
disappointing (Rich et al., 2004; Prados et al., 2006). 
It has been reported that about 89.6% of tumours had at least one alteration in the PI3K pathway 
and 39% had two or more (Cameron et al., 2013). AKT is a master regulator in this pathway that 
has shown to promote chemo-resistance (Hafsi et al., 2012). Phosphorylation of AKT especially 
at Ser473 is associated with resistance to chemotherapy/radiotherapy (Xing et al., 2005; Kim et 
al., 2006; Tokunaga et al., 2006). Moreover, over expression of EGFR is another common 
aberration in primary GBM, with a frequency of 36 to 40% (Ohgaki and Kleihues, 2007). The 
EGFR signaling pathway further stimulates AKT activity and mediates resistance to treatment 
with radiation and chemotherapy (Mrinal et al., 2005; McDowell et al., 2011; Montano et al., 
2011). In this study, the effect of AKT inhibition was investigated using allosteric and ATP 
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competitive kinase inhibitors in SKMG-3 (EGFR-amplified, PTEN-null ) and U-87 (EGFR-low, 
PTEN-null ) GBM cell lines.  
5.1 Cellular response to AKT inhibitors 
Cell viability assay was performed to assess the cytotoxic effects of the drugs. Measurement of 
enzymatic activity was used as a marker associated with viable cell number. Presumably, 
NADPH or NADH dependent dehydrogenase enzymes convert a substrate (tetrazolium) to a 
colored product (formazan) that is apparently directly proportional to the number of viable cells 
present. When cells die, they lose the ability to convert the substrate (Berridge et al., 2005). 
In this study, one allosteric and three ATP competitive kinase inhibitors of AKT were used to 
assess the cellular viability of two GBM cell lines. AKT plays a key role in cell survival and 
proliferation. Both cell lines are PTEN-null subtypes. PTEN is a tumour suppressor that acts as a 
negative regulator of PI3K-AKT-mTOR signaling axis (Georgescu, 2010). In previous research 
it has been shown that AKT is constitutively activated in these cell lines (Daphne et al., 1998; 
Christopher et al., 2003). Therefore, inhibiting AKT activity by AKT inhibitors can be a 
potential therapeutic approach in GBM.  
ATP competitive kinase inhibitors compete with ATP for occupying the ATP binding sites of 
AKT (Melissa et al., 2014). As such, inhibition of AKT activity might be delayed since some of 
the AKT could be occupied with ATP and become active. In this study, two ATP competitive 
kinase inhibitors (GSK-690693 and GDC-0068) failed to demonstrate any therapeutic efficacy in 
U-87 cell line and induced cell death only at a high dose above physiological range (Figure 11: 
A; Figure 12: A). In contrast, SKMG-3 cell line was sensitive for these drugs at <10 μM (Figure 
11: A; Figure 12: A). These results demonstrate the need to identify molecular biomarkers for 
subgroups responding to targeted therapies.  
Interestingly, another ATP competitive kinase inhibitor, GSK-2141795, exerted potent 
therapeutic efficacy in both cell lines. IC50 values of GSK-2141795 in U-87 and SKMG-3 cell 
lines were 9.7 and 4.4 μM respectively (Figure 14: A). The specific molecular underpinnings 
explaining this is unclear, but may be due to more efficient inhibition of the phosphorylation site, 
or from nonspecific interactions to other kinases of the AGC family (Lindsley et al., 2007). In 
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this regard, some key kinases might have been inhibited along with AKT by this inhibitor. These 
off targets could be assessed by mass spectrometry or protein kinase arrays (Gafken et al., 2006; 
Todd et al., 2013).  
Recent reports have indicated that allosteric inhibitors might provide a superior efficacy over 
ATP competitive kinase inhibitors. The rationale for this is due to the fact that as allosteric 
inhibitors do not compete with ATP that render maximum inhibition of AKT by binding to the 
PH domain of AKT (Mohd et al., 2014). In this study, both of the GBM cell lines responded very 
well to the allosteric inhibitor. IC50 values of MK-2206 in U-87 and SKMG-3 cells were 9.3 and 
6.1 μM respectively (Figure 13: A). This result was similar to the previous data (Figure 11: A; 
Figure 12: A; Figure 14: A) where it was shown that SKMG-3 cells were more sensitive than U-
87 cells to AKT inhibitors. The two inhibitors (MK-2206 and GSK-2141795) that demonstrated 
potent physiological therapeutic efficacy in both cell lines were used for subsequent studies.  
5.2 Clonogenic potential of GBM cell lines 
The colony forming ability of both SKMG-3 and U-87 cells was assessed by comparing 
increasing concentrations of the AKT inhibitors and control (DMSO) (Figure 15; Figure 16). 
Usually only a fraction of the seeded cells possesses the capacity to form colonies (Haloom et 
al., 2011) and one macroscopic colony is considered to consist of at least 50 cells (Nicolaas et 
al., 2006). In this study, both SKMG-3 and U-87 cells were able to form colonies. However, U-
87 cells (Figure 16: A) exhibited slower growth rate than SKMG-3 cells (Figure 15: A) as 
determined by their colony forming capacity in the control group. These results are supported by 
other reports showing that U-87 cells have a low proliferative index compared to other GBM cell 
lines (Xin et al., 2012). In both cell lines, proliferation is regulated by the PI3K-AKT pathway 
(Christopher et al., 2003; Maria et al., 2013). Serum factors also contribute to maintain the 
phosphorylation of AKT in cancer cell lines (Christopher et al., 2003). 
Since SKMG-3 is the only glioma cell line maintaining the EGFR amplification in vitro, most 
studies on this cell line has been related to EGFR signaling and inhibition (Christopher et al., 
2003). EGFR inhibitors such as erlotinib and gefitinib have been shown to attenuate glioma cell 
proliferation (Mellinghoff et al., 2005; Carrasco et al., 2011) but the results from the clinical 
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trials have not demonstrated any benefit on overall survival (Brandes et al., 2008). This is mainly 
attributed to intra tumoural heterogeneity of EGFR-amplified GBM cells which causes resistance 
to EGFR inhibitors (Alexander et al., 2013). Moreover, phosphatase and tensin homolog (PTEN) 
mutation induces hyperactivation of the PI3K/AKT pathway that renders glioma cells resistant to 
EGFR inhibition (Fan et al., 2007). A phase-I clinical trial has shown that GBM tumours that 
express high levels of phosphorylated AKT did not respond to erlotinib treatment (Haas-Kogan 
et al., 2005). 
In this study, the antitumoural effect of MK-2206 and GSK-2141795 were assessed in U-87 and 
SKMG-3 cells. Both drugs impaired the colony forming ability of the cell lines in a dose 
dependent manner (Figure 15; Figure 16). The results suggest that AKT is a key regulator of 
cellular proliferation and clonogenicity. SKMG-3 cells completely lost the clonogenic potential 
at 7 µm concentration of both inhibitors (Figure 15), while some colonies of U-87 cells were still 
viable (Figure 16).  
5.3 Status of downstream AKT substrates and cellular fate 
In most cases, intracellular signaling cascades are regulated by either phosphorylation or 
dephosphorylation of signaling components (Cooper et al., 2000). Activation of AKT induces 
tumourigenicity in a variety of cancer types by phosphorylating of its downstream substrates 
(James et al., 2007). In this study, the AKT inhibitors attenuated the enzymatic activity of AKT 
at 9 μM, as determined by a decreased phosphorylation of PRAS40, one of the major 
downstream targets of AKT (Figure 17: A, B; Figure 18: A, B). PRAS40 is a raptor interacting 
protein that binds and inhibits mTORC1 activity (Sancak et al., 2007). The mechanism of action 
of the two different types of AKT inhibitors was different. MK-2206 led to dephosphorylation of 
AKT while GSK-2141795 induced hyperphosphorylation (Figure 17: A; Figure 18: A).  
The inhibitors induced rapid apoptosis in SKMG-3 cells as determined by cleaved caspase 3 
(Figure 17: A). Activation of caspase 3 is a hallmark of apoptosis (Shobu et al., 1998). All 
caspases are synthesized as proenzymes and activated by proteolytic cleavage (Shobu et al., 
1998). Activated caspase 3 further cleaves several intracellular substrates (Nicholson and 
Thornberry, 1997). In this study, full length PARP was cleaved by the activated caspase 3 
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(Figure 17: A). These results were in line with previous reports describing that AKT inhibitors 
could induce apoptosis (Dana et al., 2009).  
In the MTS data, it was shown that U-87 cells also died in response to the drugs treatment. 
Though the apoptotic pathway regulated by caspase 3 was prevailed in this cell line as 
determined by using Staurosporine as a positive control (Figure 19); however, apoptosis was not 
detectable upon AKT inhibition (Figure 18: A). Staurosporine is commonly used as a positive 
control for induction of apoptosis (Chafké et al., 2001). In future studies, autophagic markers 
will be investigated in this cell line because it has been reported that mTORC1, a downstream 
substrate of AKT, phosphorylates autophagy-related protein-13 (ATG13) and Unc-51 like 
autophagy activating kinase-1 (ULK1) to block the initiation of autophagy (Zoncu et al., 2011). 
As in this study, AKT activity was inhibited by AKT inhibitors which in turn possibly 
diminished mTORC1 activity. This diminished activity of mTORC1 could possibly induce 
autophagy in U-87 cells. Although autophagy is considered a protector against cell death 
(Mizushima, 2007), the “Nomenclature Committee” on cell death has proposed that “autophagic 
cell death” is another type of “active” programmed death (Galluzzi et al., 2012).  
In both cell lines, GAPDH was assessed as a loading control to ensure equal loading of protein in 
each lane of the gel and for protein normalization. GAPDH is a metabolic enzyme and the levels 
of this protein can vary depending on the cellular context (Nicholls et al., 2012). However, in 
this study the levels of GAPDH were stable in both control and drug treated groups, hence other 
loading controls were not further assessed. 
5.4 Immunofluorescence staining of phospho-AKT 
In the present study, the phosphorylation status of AKT-Ser473 in control and drug treated 
groups was assessed by immunofluorescence microscopy. The allosteric drug substantially 
reduced phosphorylation of AKT-Ser473 in SKMG-3 (Figure 20: B) and U-87 cells (Figure 21: 
B) at 6 and 7 μM respectively. The ATP competitive kinase inhibitor hyperphosphorylated AKT-
Ser473 in SKMG-3 (Figure 20: C) and U-87 cells (Figure 21: C) at 6 and 7 μM respectively. 
However, the levels of pan-AKT were not assessed. Western blot analyses showed that the levels 
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of pan-AKT were stable in control and drug treated groups. The primary and secondary antibody 
controls were not checked in this study but will be considered in future experiments. 
Primary antibody control is crucial to assess the specificity of the primary antibody to the 
antigen. The most commonly used approach is to knock out the gene which codes the target 
protein. As the protein of interest is not expressed there should be no signal (Burry, 2011). 
Auto-fluorescence can cause unreliable demonstration and measurement of the levels of the 
target protein. This is usually happened by nonspecific binding of the secondary antibody. In this 
regard, secondary antibody control is often used in immunofluorescence microscopy. This is 
performed by eliminating the primary antibody. In theory, signal should not be detected as there 
is no primary antibody available to bind with the secondary antibody. However, there are several 
potential pitfalls with this method. Nonspecific binding of the secondary antibody can result 
from binding to unbound aldehydes from the fixative or cell components such as histones. To 
solve this problem, BSA is commonly used as a blocking buffer to quench the charged sites.  
Moreover, the Fc region of the secondary antibody can bind to the cellular Fc receptors. This can 
be solved by using the Fc-end of an IgG antibody that only binds with the Fc receptors and 
without the propensity to bind other antigens. Normal serum from the same species is commonly 
used to quench Fc receptors (Burry, 2011). 
In this study, two AKT inhibitors inhibited the activity of all three isoforms of AKT. As such, 
isoform specific phosphorylation of AKT was not investigated. In generally, AKT1 is localized 
to the cytoplasm, but nuclear localization is also described. AKT2 is localized to the 
mitochondria, while AKT3 is localized in both the nucleus and nuclear membrane (Santi and 
Lee, 2010). The role of AKT1 in GBM development is controversial. It has been reported that 
AKT1 did not seem to play a major role in GBM cell survival (Hideo et al., 2010). They found 
that AKT1 protein and mRNA levels were similar in GBM and normal control tissues. In their 
study, downregulation of AKT1 did not affect cell growth or survival. In contrast, in other report 
it has been shown that AKT1 played a critical role in the development of GBMs by up regulating 
the expression of cyclin D and matrix metalloproteinase-9 (MMP9) (Jian et al., 2011). Cell cycle 
progression is regulated by cyclin D which is frequently deregulated in cancer, leading to 
uncontrolled cell proliferation (Elizabeth et al., 2011). Matrix metalloproteinase-9 (MMP9) was 
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found to enhance invasiveness in primary GBM (Gheeyoung et al., 2002; Carsten et al., 2012). 
In future studies, a panel of GBM cell lines will be assessed to identify the exact role of AKT1 in 
GBMs. Furthermore, both AKT2 and AKT3 have been shown to stimulate GBM development 






















In this study, the therapeutic efficacy of AKT allosteric and ATP competitive inhibitors was 
investigated in EGFR-amplified SKMG-3 and EGFR-low U-87 cell lines. The IC50 values of 
AKT inhibitors were determined by cellular viability assay indicating that SKMG-3 cell line was 
more susceptible to AKT inhibition. These results were further validated by clonogenic assay. In 
clonogenic assay, both drugs completely inhibited colony forming ability of SKMG-3 cells at 7 
μM dose while the effects were relatively less pronounced in U-87 cell line. Western blotting 
analyses demonstrated that both drugs inhibited AKT activity in both GBM subtypes as 
determined by dephosphorylation of PRAS40, a downstream target of AKT. Furthermore, both 
drugs induced rapid apoptosis in SKMG-3 cell line but failed to induce apoptosis in U-87 cell 
line upon AKT inhibition. In essence, EGFR-amplified SKMG-3 cells are more sensitive to AKT 















To further substantiate the discrepant findings on apoptosis in U-87 cells, flow cytometry based 
on annexin-V and propidium iodide (PI) staining will be performed. In short, annexin-V and PI 
recognize apoptotic and necrotic cells respectively (Aja et al., 2011). During the early phase of 
apoptosis phosphatidyl serine is translocated from the inner to the outer leaflet of the plasma 
membrane. Phosphatidyl serine is then bound by annexin-V, labeled with a green fluorophore. 
However, cell membrane loses its integrity and becomes leaky in late apoptotic or necrotic 
events hence PI enters into cells and intercalates into nucleic acids, and displays red fluorescence 
(Vermes et al., 2000).  
As EGFR-amplified GBM cells responded particularly well to AKT inhibitors, these two AKT 
inhibitors should be tested in primary cell lines derived from surgical specimens from GBM 
patients to determine whether EGFR positive tumours in general respond well to AKT targeted 
therapy. Furthermore, EGFR inhibitors can be tested together with AKT inhibitors as 
combinatorial therapy. To further elucidate this, immunodeficient mice will be implanted with 
tumour spheroids derived from EGFR-amplified cell lines and treated with both AKT and EGFR 
inhibitors. Moreover, Temozolomide, the current standard of care for GBM can be tested with 
AKT inhibitors for possible synergistic effects (Hegi et al., 2005; Kaina et al., 2007; Weller et 
al., 2013). The ultimate goal of this study is to identify improved therapeutic approaches for 
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